<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085276</url>
  </required_header>
  <id_info>
    <org_study_id>JS001-026-III-TNBC</org_study_id>
    <nct_id>NCT04085276</nct_id>
  </id_info>
  <brief_title>Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment</brief_title>
  <acronym>TORCHLIGHT</acronym>
  <official_title>A Randomized, Double-Blind, Multicenter, Phase III Study of Toripalimab(JS001) in Combination With Nab-Paclitaxel Versus Placebo Plus Nab-Paclitaxel for Patients With Metastatic or Recurrent Triple-Negative Breast Cancer With or Without Systemic Treatment (TORCHLIGHT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, randomized, double-blind study will evaluate the efficacy and safety of
      Toripalimab (JS001) combined with nab-paclitaxel compared with placebo combined with
      nab-paclitaxel for first/second line treatment of metastatic or recurrent triple-negative
      breast cancer (TNBC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Intend to Treat patients.</measure>
    <time_frame>Up to approximately 35 months from first patient in.</time_frame>
    <description>PFS is defined as the time from randomization to the first occurrence of PD, as determined by the investigator using RECIST v1.1, or death due to any cause during the study, whichever occurs first. PD is defined as greater than or equal to (&gt;/=) 20 percent (%) relative increase and &gt;/=5 millimeter (mm) of absolute increase in the sum of diameters (SD) of target lesions (TLs), taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS assessed by BICR using RECIST v1.1 in PD-L1 positive patients</measure>
    <time_frame>Up to approximately 35 months from first patient in.</time_frame>
    <description>PFS is defined as the time from randomization to the first occurrence of PD, as determined by the investigator using RECIST v1.1, or death due to any cause during the study, whichever occurs first. PD is defined as greater than or equal to (&gt;/=) 20 percent (%) relative increase and &gt;/=5 millimeter (mm) of absolute increase in the sum of diameters (SD) of target lesions (TLs), taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) assessed by investigator using RECIST v1.1. Analyzing among Intend to Treat (ITT) and PD-L1 positive patients respectively.</measure>
    <time_frame>Up to approximately 35 months from first patient in.</time_frame>
    <description>PFS is defined as the time from randomization to the first occurrence of PD, as determined by the investigator or BICR using RECIST v1.1, or death due to any cause during the study, whichever occurs first. PD is defined as greater than or equal to (&gt;/=) 20 percent (%) relative increase and &gt;/=5 millimeter (mm) of absolute increase in the sum of diameters (SD) of target lesions (TLs), taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) assessed by BICR or investigators using RECIST v1.1. Analyzing among Intend to Treat (ITT) and PD-L1 positive patients respectively.</measure>
    <time_frame>Up to approximately 35 months from first patient in.</time_frame>
    <description>ORR is defined as the rate of CR(Complete Response) or PR (Partial Response), as determined by BICR using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR) assessed by BICR or investigators using RECIST v1.1. Analyzing among Intend to Treat (ITT) and PD-L1 positive patients respectively.</measure>
    <time_frame>Up to approximately 35 months from first patient in.</time_frame>
    <description>DoR is defined as the time period from the date of initial CR or PR until the date of PD or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) assessed by BICR or investigators using RECIST v1.1. Analyzing among Intend to Treat (ITT) and PD-L1 positive patients respectively.</measure>
    <time_frame>Up to approximately 35 months from first patient in.</time_frame>
    <description>DcR is defined as the sum rate of CR, PR and SD (Stable Disease), as determined by BICR or investigators using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS). Analyzing among Intend to Treat (ITT) and PD-L1 positive patients respectively.</measure>
    <time_frame>Up to approximately 35 months from first patient in.</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS rate at 12 months. Analyzing among Intend to Treat (ITT) and PD-L1 positive patients respectively.</measure>
    <time_frame>Up to approximately 48 months from first patient in.</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS rate at 24 months. Analyzing among Intend to Treat (ITT) and PD-L1 positive patients respectively.</measure>
    <time_frame>Up to approximately 48 months from first patient in.</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in PD-L1 positive patients.</measure>
    <time_frame>Up to approximately 35 months from first patient in.</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in safety and tolerability as assessed by the occurrence of adverse events. Analyzing among Intend to Treat (ITT) and PD-L1 positive patients respectively.</measure>
    <time_frame>From Day 1 to death from any cause, assessed up to end of study (up to approximately 30 months)</time_frame>
    <description>fety is defined as risk to the subject; tolerablity is which represents the degree to which overt adverse effects can be tolerated by the subject/patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in the scores of health-related quality of life (HRQol) evaluated by EORTC QLQ-C30. Analyzing among Intend to Treat (ITT) and PD-L1 positive patients respectively.</measure>
    <time_frame>From Day 1 to death from any cause, assessed up to end of study (up to approximately 30 months)</time_frame>
    <description>Evaluated by European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in the scores of health-related quality of life (HRQol) evalued by EORTC QLQ-BR23. Analyzing among Intend to Treat (ITT) and PD-L1 positive patients respectively.</measure>
    <time_frame>From Day 1 to death from any cause, assessed up to end of study (up to approximately 30 months)</time_frame>
    <description>Evaluated by European Organisation for Research and Treatment of Cancer (EORTC) QLQ-BR23</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in the scores of disease/treatment-related symptoms evaluted by ECOG Performance Status. Analyzing among Intend to Treat (ITT) and PD-L1 positive patients respectively.</measure>
    <time_frame>From Day 1 to death from any cause, assessed up to end of study (up to approximately 30 months)</time_frame>
    <description>Evaluated by Eastern Cooperative Oncogloy Group (ECOG) Performance Status</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Triple-Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>JS001 Plus Nab-Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive both JS001 and Nab-Paclitaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Plus Nab-Paclitaxel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive both placebo and Nab-Paclitaxel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS001</intervention_name>
    <description>JS001 240mg, i.v., q3w; Other name: Toripalimab</description>
    <arm_group_label>JS001 Plus Nab-Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-Paclitaxel</intervention_name>
    <description>Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w</description>
    <arm_group_label>JS001 Plus Nab-Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, i.v., q3w;</description>
    <arm_group_label>Placebo Plus Nab-Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-Paclitaxel</intervention_name>
    <description>Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w</description>
    <arm_group_label>Placebo Plus Nab-Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Metastatic or recurrent triple negative breast cancer (TNBC);

          -  Histologically confirmed diagnosis of TNBC characterized by estrogen-receptor negative
             (ER-), progesterone receptor negative (PR-) and human epidermal growth factor-2
             receptor negative (HER2-);

          -  Eligible for taxane monotherapy;

          -  No more than one line of chemotherapy in metastatic setting;

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

          -  Life expectancy of 12 weeks or more;

          -  At least one measurable lesion per RECIST v1.1;

          -  Demonstrate adequate hematologic and organ functions as defined in the protocol

        Exclusion Criteria:

        Prior treatment with taxane as first line treatment;

          -  Prior treatment with PD-1 antibody, PD-L1 antibody, PD-L2 antibody, or CTLA4 antibody
             (or any other antibody acting on T cell co-stimulation or checkpoint pathway)

          -  MRI assessment during screening or previous imaging studies confirmed active or
             untreated brain metastases. Patients previously treated with local treatment of brain
             metastases has been stable for ≥ 1 month, and have stopped systemic hormonal therapy
             (&gt;10 mg/d prednisone or equivalent) &gt; 4 weeks before randomization can participate in
             the study;

          -  Meningeal carcinomatosis;

          -  Pregnancy or lactation;

          -  Active hepatitis B or hepatitis C.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Er Xiao</last_name>
    <phone>010-8517-2616</phone>
    <email>js001tnbcstudy@junshipharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Fifth Medical Center of PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongqiang Zhang</last_name>
      <email>jgb947797@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junlan Yang</last_name>
      <email>301jgb@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shu Wang</last_name>
      <email>rmyyyljd@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Shougang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xueli Mo</last_name>
      <email>bdsggcp@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Hebei University</name>
      <address>
        <city>Baoding</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimin Zang</last_name>
      <email>hdfydbs@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Qian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Cheng</last_name>
      <email>xjy0202@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiuwei Cui</last_name>
      <email>wangfei5780@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quchang Ouyang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Chengde Medical University</name>
      <address>
        <city>Chengde</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingshan Li</last_name>
      <email>cyfy2279473@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xin Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Man Li</last_name>
      <email>dy2y15@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Foshan</name>
      <address>
        <city>Foshan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danmei Pang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuan Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kun Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shusen Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Lin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Women and Children's Hospital of Guangdong Province</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anqin Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peifen Fu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yiding Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojia Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingyuan Zhang</last_name>
      <email>sylcyj609@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anhui Province Hospital &amp; The First Affiliated Hospital of USTC</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yueyin Pan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kangsheng Gu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhendong Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospita of Inner Mongolia Medical University</name>
      <address>
        <city>Hohhot</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wuyun Su</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongsheng Wang</last_name>
      <email>ywb234@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yunnan Cancer Hospital</name>
      <address>
        <city>Kunming</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianyun Nie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linyi Cancer Hospital</name>
      <address>
        <city>Linyi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingfen Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospita of of Southwest Medical University</name>
      <address>
        <city>Luzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yunwei Han</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Cancer Hospital</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yudong Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biao Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Nanchang</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunwei Xie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lili Zhang</last_name>
      <email>ctc@jszlyy.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongmei Yin</last_name>
      <email>jsphkj@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haibo Wang</last_name>
      <email>jidi1767@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan Sheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongxia Wang</last_name>
      <email>shiyigcp@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital&amp;Intitute</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Sun</last_name>
      <email>lnszlysbxz@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue'e Teng</last_name>
      <email>ydyygcp@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cuizhi Geng</last_name>
      <email>zls_gcp@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Affiliated to Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinhong Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huihua Xiong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Cheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangnan University（Wuxi NO.4 People's Hospital）</name>
      <address>
        <city>Wuxi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohong Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilin Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangyang Central Hospital</name>
      <address>
        <city>Xiangyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tienan Yi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of The PLA Air Force Military Medical University</name>
      <address>
        <city>Xian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helong Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinlan Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zheng'zhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shundong Cang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yan</last_name>
      <email>hnszlyyyb@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

